E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114
The results highlight the antitumor activity and manageable safety profile of E7389-LF, indicating the potential of E7389-LF as a 1L treatment for patients with HER2-negative breast cancer, warranting further study.